Question-and-Answer Session
Operator
Thank you, Dr. Bahcall. Ladies and gentlemen, we will now be conducting a question-and-answer session. (Operator Instructions) Thank you. And our first question comes from the line of Mike King with Rodman & Renshaw. Please proceed with your question.
Mike King - Rodman & Renshaw
Hi, good morning, guys. Thanks for taking my question.
Safi Bahcall
Good morning, Mike.
Mike King - Rodman & Renshaw
Just a couple of quick ones. Safi, with regards to the ASCO presentation by Lawson, that will not have, include final mortality data in that presentation?
Eric Jacobson
Hi, Mike. This is Eric Jacobson.
Mike King - Rodman & Renshaw
Hey, Eric.
Eric Jacobson
No, that will not be focusing on overall survival.
Mike King - Rodman & Renshaw
And then I guess I missed where the final survival data would be? I know you said later in '08. Have you specified the venue?
Eric Jacobson
We have not specified the venue. As you know, we presented overall survival last year. We just have follow-up now.
Mike King - Rodman & Renshaw
Right.
Eric Jacobson
Following patients for two years, and that's going to be presented later this year.
Mike King - Rodman & Renshaw
Okay. Will a publication have, where will it cut off the survival? Is that going to be at one year in the article?
Eric Jacobson
We are not really going into details about what is in that publication, but as of our previous presentations, we were cutting it off at one year.
Mike King - Rodman & Renshaw
Okay. And then just could I get your thoughts on, it's great that things are going well with the enrollment. Just when enrollment goes more quickly than companies expect, oftentimes patients are enrolled that don't specifically meet the entry criteria. How can we be sure as investors that these patients are being QAed, and that they are in fact meeting the specifications of the enrollment and exclusive criteria?
Eric Jacobson
Mike, these patients are all meeting all of the formal inclusion criteria. We have very close monitoring of the sites. We have an IVRS system that the sites have to put criteria in to, in order for them to enter into the trial. So, between our close monitoring by the CRAs and the IVRS system, we are quite confident that these patients are meeting our formal inclusion criteria.
Mike King - Rodman & Renshaw
- To read the full transcript on Seeking Alpha, click here »
